Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial

MLA

Hong Wang, et al. “Five-Year Follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) Trial.” American Heart Journal, vol. 163, Mar. 2012, pp. 438–45. EBSCOhost, https://doi.org/10.1016/j.ahj.2011.11.019.

APA

Hong Wang, J.J. Popma, Oluseun Alli, Michael H. Sketch, Paul S. Teirstein, Sidney A. Cohen, Laura Mauri, Patricia A. Schleckser, Lowell F. Satler, & David R. Holmes. (2012). Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial. American Heart Journal, 163, 438–445. https://doi.org/10.1016/j.ahj.2011.11.019

Chicago

Hong Wang, J.J. Popma, Oluseun Alli, Michael H. Sketch, Paul S. Teirstein, Sidney A. Cohen, Laura Mauri, Patricia A. Schleckser, Lowell F. Satler, and David R. Holmes. 2012. “Five-Year Follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) Trial.” American Heart Journal 163 (March): 438–45. doi:10.1016/j.ahj.2011.11.019.